CSS
LGND icon

Cubist Systematic Strategies’s Ligand Pharmaceuticals LGND Stock Holding History

Cubist Systematic Strategies’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,149
Closed -$1.7M – 3951
2023
Q1 		$1.7M Sell
23,149
-28,005
-55% -$1.99M 0.01% 1784
2022
Q4 		$3.42M Buy
51,154
+35,249
+222% +$2.29M 0.02% 1365
2022
Q3 		$854K Sell
15,905
-12,592
-44% -$740K ﹤0.01% 2752
2022
Q2 		$1.59M Buy
28,497
+8,544
+43% +$485K 0.01% 2068
2022
Q1 		$1.4M Buy
19,953
+14,958
+299% +$1.09M 0.01% 1770
2021
Q4 		$481K Buy
4,995
+1,619
+48% +$150K ﹤0.01% 2478
2021
Q3 		$293K Sell
3,376
-5,944
-64% -$460K ﹤0.01% 2375
2021
Q2 		$763K Sell
9,320
-21,696
-70% -$1.8M 0.01% 1743
2021
Q1 		$2.95M Sell
31,016
-9,168
-23% -$867K 0.04% 766
2020
Q4 		$2.49M Buy
40,184
+27,923
+228% +$1.59M 0.03% 809
2020
Q3 		$729K Sell
12,261
-8,743
-42% -$597K 0.01% 1513
2020
Q2 		$1.47M Sell
21,004
-20,081
-49% -$1.27M 0.03% 974
2020
Q1 		$1.86M Buy
41,085
+37,631
+1,089% +$2.13M 0.05% 498
2019
Q4 		$225K Sell
3,454
-73,086
-95% -$4.88M ﹤0.01% 1989
2019
Q3 		$4.75M Buy
76,540
+31,980
+72% +$2.01M 0.09% 313
2019
Q2 		$3.17M Buy
44,560
+11,224
+34% +$827K 0.06% 463
2019
Q1 		$2.61M Buy
33,336
+21,148
+174% +$1.6M 0.08% 335
2018
Q4 		$1.03M Buy
+12,188
New +$1.3M 0.05% 551
2017
Q1 		– Sell
-5,976
Closed -$379K – 1738
2016
Q4 		$379K Buy
+5,976
New +$377K 0.03% 831
2016
Q3 		– Sell
-4,593
Closed -$342K – 1778
2016
Q2 		$342K Buy
+4,593
New +$341K 0.02% 1001
2016
Q1 		– Sell
-5,368
Closed -$363K – 1735
2015
Q4 		$363K Buy
+5,368
New +$331K 0.02% 1002
2015
Q2 		– Sell
-7,539
Closed -$363K – 1938
2015
Q1 		$363K Buy
7,539
+5
+0.1% +$192 0.02% 1141
2014
Q4 		$250K Sell
7,534
-763
-9% -$24.8K 0.01% 1354
2014
Q3 		$243K Buy
+8,297
New +$275K 0.01% 1241

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Cubist Systematic Strategies's LGND Position: Q2 2023 in Review

Cubist Systematic Strategies sold out of Ligand Pharmaceuticals (LGND) in Q2 2023, closing a stake of 23,149 shares — an estimated $1.7M sold.

Cubist Systematic Strategies first reported a position in LGND in Q3 2014 and held it in 24 quarters. The position peaked at $4.75M in Q3 2019. 204 funds tracked by Wall St. Rank hold LGND as of Q2 2023.

  • Cubist Systematic Strategies reported no remaining Ligand Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 23,149 Ligand Pharmaceuticals shares in Q2 2023, an estimated $1.7M.
  • Cubist Systematic Strategies first reported a position in Ligand Pharmaceuticals in Q3 2014 and held it in 24 quarters.
  • Cubist Systematic Strategies's Ligand Pharmaceuticals position peaked at $4.75M in Q3 2019.
  • 204 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2023.

Based on Cubist Systematic Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.